Ketamine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound Guided Bilateral Superficial Cervical Plexus Block in Thyroidectomy

NCT07838831 | Completed

• 1 other identifier: 36264MS1012/7/25
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to compare the analgesic efficacy of Dexmedetomidine and Ketamine as adjuvants to Bupivacaine in ultrasound-guided Bilateral SCPB in patients undergoing thyroidectomy

Conditions

Thyroidectomy; Bupivacaine; Dexmedetomidine

Keywords

dexmedetomidine; thyroidectomy; ketamine; superficial cervical plexus bl

Outcome Measures

Primary Outcomes (1)

• Morphine consumption

  total 24 hours Morphine consumption(mg)

  24 hours

Secondary Outcomes (1)

• Assessment of post operative pain

  immediately (T0),15 mins(T1),30 mins(T2),1 hour(T3),2 hours(T4),4 hours(T5)8 hours(T6),12 hours(T7),18 hours(T8),24 hours(T9) after arrival to recovery room

Study Arms (3)

Group C (Control group)

PLACEBO COMPARATOR

Patients will only receive bilateral SCPB with 45mg bupivacaine diluted with normal saline (18 mL; 9 mL on each side) after intubation and before surgical incision.

Drug: Group C (Control group)

Group D (Dexmedetomidine group)

EXPERIMENTAL

Patients will receive general anesthesia plus US guided Bilateral SCPB with 45mg bupivacaine diluted with normal saline to 16mL and 1 μg/kg dexmedetomidine diluted with normal saline to 2mL (total volume, 18 mL; 9 mL on each side) after intubation and before surgical incision.

Drug: Group D (Dexmedetomidine group)

Group K (Ketamine group)

EXPERIMENTAL

Patients will receive general anesthesia plus US guided Bilateral SCPB with 45mg bupivacaine diluted with normal saline to 16 mL and 1 mg/kg ketamine diluted with normal saline to 2 mL (total volume, 18 mL; 9 mL on each side) after intubation and before surgical incision.

Drug: Group K (Ketamine group)

Interventions

Group C (Control group) DRUG

Patients will only receive bilateral SCPB with 45mg bupivacaine diluted with normal saline (18 mL; 9 mL on each side) after intubation and before surgical incision.

Group C (Control group)

Group D (Dexmedetomidine group) DRUG

Patients will receive general anesthesia plus US guided Bilateral SCPB with 45mg bupivacaine diluted with normal saline to 16mL and 1 μg/kg dexmedetomidine diluted with normal saline to 2mL (total volume, 18 mL; 9 mL on each side) after intubation and before surgical incision.

Group D (Dexmedetomidine group)

Group K (Ketamine group) DRUG

Patients will receive general anesthesia plus US guided Bilateral SCPB with 45mg bupivacaine diluted with normal saline to 16 mL and 1 mg/kg ketamine diluted with normal saline to 2 mL (total volume, 18 mL; 9 mL on each side) after intubation and before surgical incision.

Group K (Ketamine group)

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged more than 18 years
• American Society of Anesthesiologists physical status I or II
• scheduled for elective thyroid surgery will be included in the study.

You may not qualify if:

• Patients who refuse to participate in the study.
• Patients presented with mental and memory dysfunction.
• Patients with history of allergy to local anesthetics.
• Patients with history of chronic use of pain killers )most days for more than 3 months).
• Patients presented with skin or soft tissue infection at the proposed site of needle.
• Pre-existing major organ dysfunction such as hepatic or renal impairment.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, Egypt

Location

MeSH Terms

Interventions

Control Groups

Intervention Hierarchy (Ancestors)

Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Research Design; Methods

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: September 18, 2026
• First Posted: September 24, 2026
• Study Start: August 31, 2025
• Primary Completion: August 30, 2026
• Study Completion: August 30, 2026
• Last Updated: September 24, 2026

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF

Locations

EG (1)